MEGL vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 31, 2026

MEGL

50.7
AI Score
VS
HIVE Wins

HIVE

57.6
AI Score

Investment Advisor Scores

MEGL

51score
Recommendation
HOLD

HIVE

58score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MEGL HIVE Winner
Revenue 1.48M 297.79M HIVE
Net Income -1.07M -148.45M MEGL
Net Margin -72.1% -49.8% HIVE
ROE -6.9% -28.0% MEGL
ROA -6.6% -23.2% MEGL
Total Assets 16.17M 639.15M HIVE
Cash 15.51M 23.11M HIVE
Current Ratio 38.86 1.10 MEGL

Relative Price Performance (Last 90 Days)

MEGL 1M: -12.9% · 3M: +1.3% HIVE 1M: -10.8% · 3M: +18.9%

Current Technical Phase

MEGL

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 50.0 · Price: $1.19

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 44

RSI (14): 43.5 · Price: $2.89

Fundamentals Snapshot

Metric MEGL HIVE
Market Cap
Forward P/E 0.0 -5.7
Trailing P/E
Revenue (TTM)
Revenue Growth 0.3% 1.3%
Gross Margin 0.7% 0.4%
Operating Margin -0.9% -0.8%
EPS -0.21 -0.66
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.